Form 4 for DLB Dolby Laboratories, Inc.
Accepted 2025-11-26 00:00:00 ET · period of report 2025-11-24 · accession 0001193125-25-301000 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMTI | 2025-11-26 | 2025-11-24 | DLB | YEAMAN KEVIN J | Pres, CEO, Dir | M - OptEx | $51.59 | +36.7K | 151.4K | +32% | +$1.89M |
| DTI | 2025-11-26 | 2025-11-24 | DLB | YEAMAN KEVIN J | Pres, CEO, Dir | S - Sale+OE | $66.91 | -36.7K | 114.7K | -24% | -$2.46M |
| DTI | 2025-11-26 | 2025-11-26 | DLB | YEAMAN KEVIN J | Pres, CEO, Dir | G - Gift | $0.00 | -16.3K | 98.4K | -14% | $0 |
| DMTI | 2025-11-26 | 2025-11-24 | DLB | YEAMAN KEVIN J | Pres, CEO, Dir | M - OptEx | $0.00 | -36.7K | 23.8K | -61% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-11-24 | M | A | 25,000 | $45.50 | 139,725 | I By a trust | — | — | (F1) By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
| 2 | Common | Class A Common Stock | 2025-11-24 | M | A | 11,699 | $64.60 | 151,424 | I By a trust | — | — | (F1) By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
| 3 | Common | Class A Common Stock | 2025-11-24 | S | D | 36,699 | $66.91 | 114,725 | I By a trust | — | — | (F2) The shares were sold in multiple transactions at prices ranging from $66.53 to $67.37, inclusive. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The shares were sold pursuant to a 10b5-1 trading plan adopted on February 28, 2025. (F1) By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
| 4 | Common | Class A Common Stock | 2025-11-26 | G | D | 16,348 | $0.00 | 98,377 | I By a trust | — | — | (F1) By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2025-11-24 | M | D | 25,000 | $0.00 | 10,615 | I By a trust | $45.50 · — to 2026-12-15 | 25,000 Class A Common Stock | (F1) By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 (F5) This option was granted for a total of 194,399 shares of Class A Common Stock. The option exercised in this transaction was fully vested and exercisable as of the transaction date. |
| 6 | Derivative | Employee Stock Option (Right to Buy) | 2025-11-24 | M | D | 11,699 | $0.00 | 23,752 | I By a trust | $64.60 · — to 2025-12-17 | 11,699 Class A Common Stock | (F1) By the Kevin and Rachel Yeaman Family Trust dated May 14, 2009 (F6) This performance-based stock option award was granted for a total of 82,000 shares of Class A Common Stock at target. The number of shares actually earned and vested upon the achievement of total shareholder return performance criteria measured during a three-year performance period ended on December 17, 2021 was at 75% of target, or 61,500 shares. |